Thompson Davis & CO. Inc. reduced its stake in Pfizer Inc. (NYSE:PFE) by 50.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,762 shares of the biopharmaceutical company’s stock after selling 3,838 shares during the period. Thompson Davis & CO. Inc.’s holdings in Pfizer were worth $134,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Janus Henderson Group PLC raised its stake in Pfizer by 243.5% in the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after buying an additional 9,339,749 shares in the last quarter. Vanguard Group Inc. raised its stake in Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after buying an additional 9,239,499 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Pfizer in the second quarter valued at $268,389,000. Canada Pension Plan Investment Board raised its stake in Pfizer by 249.6% in the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after buying an additional 7,649,416 shares in the last quarter. Finally, Longview Partners Guernsey LTD raised its stake in Pfizer by 32.0% in the third quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock valued at $869,997,000 after buying an additional 5,901,100 shares in the last quarter. Institutional investors and hedge funds own 69.74% of the company’s stock.

Shares of Pfizer Inc. (NYSE PFE) opened at $36.41 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 52-week low of $30.90 and a 52-week high of $37.35. The company has a market capitalization of $217,030.00, a PE ratio of 22.34, a PEG ratio of 2.46 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the previous year, the firm earned $0.61 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. research analysts forecast that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

Pfizer declared that its board has initiated a share buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.74%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is 78.53%.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Insiders have sold 29,450 shares of company stock worth $1,065,220 in the last quarter. Insiders own 0.06% of the company’s stock.

A number of analysts have weighed in on PFE shares. UBS Group set a $40.00 price target on Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. BMO Capital Markets restated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a research note on Friday, November 10th. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target on the stock in a research note on Thursday, November 23rd. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Tuesday, October 3rd. Finally, Jefferies Group set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $38.83.

TRADEMARK VIOLATION NOTICE: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/thompson-davis-co-inc-has-134000-stake-in-pfizer-inc-pfe/1800900.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.